BACKGROUND: Right ventricular (RV) function and failure are key determinants of morbidity and mortality in various cardiovascular diseases. Myocardial fibrosis is regarded as a contributing factor to heart failure, but its importance in RV failure has been challenged. This study aims to assess whether myocardial fibrosis drives the transition from compensated to decompensated volume load-induced RV dysfunction. METHODS: Wistar rats were subjected to aorto-caval shunt (ACS, n = 23) or sham (control, n = 15) surgery, and sacrificed after 1 month, 3 months, or 6 months. Echocardiography, RV pressure-volume analysis, assessment of gene expression and cardiac histology were performed. RESULTS: At 6 months, 6/8 ACS-rats (75%) showed clinical signs of RV failure (pleural effusion, ascites and/or liver edema), whereas at 1 month and 3 months, no signs of RV failure had developed yet. Cardiac output has increased two- to threefold and biventricular dilatation occurred, while LV ejection fraction gradually decreased. At 1 month and 3 months, RV end-systolic elastance (Ees) remained unaltered, but at 6 months, RV Ees had decreased substantially. In the RV, no oxidative stress, inflammation, pro-fibrotic signaling (TGFβ1 and pSMAD2/3), or fibrosis were present at any time point. CONCLUSIONS: In the ACS rat model, long-term volume load was initially well tolerated at 1 month and 3 months, but induced overt clinical signs of end-stage RV failure at 6 months. However, no myocardial fibrosis or increased pro-fibrotic signaling had developed. These findings indicate that myocardial fibrosis is not involved in the transition from compensated to decompensated RV dysfunction in this model.
BACKGROUND: Right ventricular (RV) function and failure are key determinants of morbidity and mortality in various cardiovascular diseases. Myocardial fibrosis is regarded as a contributing factor to heart failure, but its importance in RV failure has been challenged. This study aims to assess whether myocardial fibrosis drives the transition from compensated to decompensated volume load-induced RV dysfunction. METHODS: Wistar rats were subjected to aorto-caval shunt (ACS, n = 23) or sham (control, n = 15) surgery, and sacrificed after 1 month, 3 months, or 6 months. Echocardiography, RV pressure-volume analysis, assessment of gene expression and cardiac histology were performed. RESULTS: At 6 months, 6/8 ACS-rats (75%) showed clinical signs of RV failure (pleural effusion, ascites and/or liver edema), whereas at 1 month and 3 months, no signs of RV failure had developed yet. Cardiac output has increased two- to threefold and biventricular dilatation occurred, while LV ejection fraction gradually decreased. At 1 month and 3 months, RV end-systolic elastance (Ees) remained unaltered, but at 6 months, RV Ees had decreased substantially. In the RV, no oxidative stress, inflammation, pro-fibrotic signaling (TGFβ1 and pSMAD2/3), or fibrosis were present at any time point. CONCLUSIONS: In the ACS rat model, long-term volume load was initially well tolerated at 1 month and 3 months, but induced overt clinical signs of end-stage RV failure at 6 months. However, no myocardial fibrosis or increased pro-fibrotic signaling had developed. These findings indicate that myocardial fibrosis is not involved in the transition from compensated to decompensated RV dysfunction in this model.
Keywords:
aortocaval shunt; fibrosis; right ventricular failure; right ventricular remodeling; right ventricular remodeling and fibrosis; tetralogy of Fallot; volume load
Authors: Diederik E van der Feen; Michel Weij; Annemieke Smit-van Oosten; Lysanne M Jorna; Quint A J Hagdorn; Beatrijs Bartelds; Rolf M F Berger Journal: J Vis Exp Date: 2017-02-11 Impact factor: 1.355
Authors: Slaven Crnkovic; Bakytbek Egemnazarov; Rachel Damico; Leigh M Marsh; Bence M Nagy; Philipp Douschan; Kwame Atsina; Todd M Kolb; Stephen C Mathai; Jody E Hooper; Bahil Ghanim; Walter Klepetko; Friedrich Fruhwald; Dirk Lassner; Andrea Olschewski; Horst Olschewski; Paul M Hassoun; Grazyna Kwapiszewska Journal: Am J Respir Crit Care Med Date: 2019-06-15 Impact factor: 21.405
Authors: J J Mercadier; A M Lompré; C Wisnewsky; J L Samuel; J Bercovici; B Swynghedauw; K Schwartz Journal: Circ Res Date: 1981-08 Impact factor: 17.367
Authors: Christopher M Haggerty; Jonathan D Suever; Arichanah Pulenthiran; Abba Mejia-Spiegeler; Gregory J Wehner; Linyuan Jing; Richard J Charnigo; Brandon K Fornwalt; Mark A Fogel Journal: J Cardiovasc Magn Reson Date: 2017-12-11 Impact factor: 5.364